Hyperparathyroidism in the elderly patient

Drugs and Aging

Volumn 21, Issue 15, 2004, Pages 1013-1024

  Sims, Rebecca ^a   Ubhi, Charanjeit ^a   Hosking, David ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIMIMETIC AGENT; CALCIUM; CINACALCET; ESTROGEN; ETIDRONIC ACID; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; R 568; RALOXIFENE; TECALCET; UNCLASSIFIED DRUG;

AGED; AGING; BONE DENSITY; BONE MINERAL; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ECHOGRAPHY; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; GERIATRIC PATIENT; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; INTRAOPERATIVE PERIOD; KIDNEY FUNCTION; MENOPAUSAL SYNDROME; META ANALYSIS; OSTEOPOROSIS; PARATHYROID ADENOMA; PARATHYROID GLAND; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID SCINTISCANNING; PARATHYROIDECTOMY; POSTMENOPAUSE OSTEOPOROSIS; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REVIEW; SPINE FRACTURE; THYROID DISEASE; TREATMENT INDICATION;

AGED; BONE DENSITY; HUMANS; HYPERPARATHYROIDISM; PARATHYROIDECTOMY;

EID: 11344285422     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200421150-00004     Document Type: Review

References (88)

1. Melton III LJ. The epidemiology of primary hyperparathyroidism in North America. J Bone Miner Res 2002; 17 Suppl. 2: N12-7
2. Lundgren E, Hagstrom EG, Lundin J, et al. Primary hyperparathyroidism revisited in menopausal women with serum calcium in the upper normal range at population-based screening 8 years ago. World J Surg 2002; 26 (8): 931-6
3. Sosa JA, Powe NR, Levine MA, et al. Cost implications of different surgical management strategies for primary hyperparathyroidism. Surgery 1998 Dec 1; 24 (6): 1028-35
4. Horowitz M, Wishart JM, Need AG, et al. Primary hyperparathyroidism. Clin Geriatr Med 1994; 10 (4): 757-75
5. Albertazzi P, Steel SA, Purdie DW, et al. Hyperparathyroidism in elderly osteopenic women. Maturitas 2002 Dec 10; 43 (4): 245-9
6. Schneider AB, Gierlowski TC, Shore-Freedman E, et al. Dose-response relationships for radiation-induced hyperparathyroidism. J Clin Endocrinol Metab 1995; 80 (1): 254-7
7. Holmberg E, Wallgren A, Holm LE, et al. Dose-response relationship for parathyroid adenoma after exposure to ionizing radiation in infancy. Radiat Res 2002; 158 (4): 418-23
8. Lepage R, Roy L, Brassard JH, et al. A non- (1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 1998; 44 (4): 805-9
9. Gao P, Scheibel S, D'Amour P, et al. Development of novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 2001; 16: 605-14
10. Hutchesson AC, Bundred NJ, Ratcliffe WA. Survival in hypercalcaemic patients with cancer and co-existing primary hyperparathyroidism. Postgrad Med J 1995; 71 (831): 28-31
11. Parfitt AM. Equilibrium and disequilibrium hypercalcaemia: new light on an old concept. Metab Bone Dis Relat Res 1979; 1: 279-93
12. Christiansen P, Steiniche T, Brixen K, et al. Primary hyperparathyroidism: short-term changes in bone remodeling and bone mineral density following parathyroidectomy. Bone 1999; 25 (2): 237-44
13. Wermers RA, Khosla S, Atkinson EJ, et al. Survival after the diagnosis of hyperparathyroidism: a population-based study. Am J Med 1998; 104(2): 115-22
14. Alveryd A, Bostrom H, Wengle B, et al. Indications for surgery in the elderly patient with primary hyperparathyroidism. Acta Chir Scand 1976; 142 (7): 491-4
15. Bilezikian JP, Potts Jr JT, Fuleihan GE, et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Bone Miner Res 2002; 17 Suppl. 2: N2-N11
16. Silverberg SJ, Shane E, Jacobs TP, et al. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery [published erratum appears in N Engl J Med 2000 Jan 13; 342 (2): 144]. N Engl J Med 1999 Oct 21; 341 (17): 1249-55
17. Silverberg SJ, Shane E, Jacobs TP, et al. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery [published erratum appears in N Engl J Med 2000 Jan 13; 342 (2): 144]. N Engl J Med 1999 Oct 21; 341 (17): 1249-55
18. Christiansen P, Steiniche T, Vesterby A, et al. Primary hyperparathyroidism: iliac crest trabecular bone volume, structure, remodeling, and balance evaluated by histomorphometric methods. Bone 1992; 13 (1): 41-9
19. Khosla S, Melton III J. Fracture risk in primary hyperparathyroidism. J Bone Miner Res 2002; 17 Suppl. 2: N103-7
20. Vestergaard P, Mollerup CL, Frokjaer VG, et al. Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ 2000; 321: 598-602
21. Agarwal G, Mishra SK, Kar DK, et al. Recovery pattern of patients with osteitis fibrosa cystica in primary hyperparathyroidism after successful parathyroidectomy. Surgery 2002; 132 (6): 1075-83
22. Henegar JR, Coleman JP, Cespedes J, et al. Glomerular calcification in hypercalcemic nephropathy. Arch Pathol Lab Med 2003; 127 (2): E80-5
23. Earm JH, Christensen BM, Frokiaer J, et al. Decreased aquaporin-2 expression and apical plasma membrane delivery in kidney collecting ducts of polyuric hypercalcemic rats. J Am Soc Nephrol 1998; 9 (12): 2181-93
24. Kwon TH, Laursen UH, Marples D, et al. Altered expression of renal AQPs and Na(+) transporters in rats with lithium-induced NDI. Am J Physiol Renal Physiol 2000; 279 (3): F552-64
25. Li C, Wang W, Kwon TH, et al. Downregulation of AQP1, -2, and -3 after ureteral obstruction is associated with a long-term urine-concentrating defect. Am J Physiol Renal Physiol 2001; 281 (1): F163-71
26. McDonald AC, Bruce DG, Smith DJ. Primary hyperparthyroidism in an elderly woman: surgical reversibilty of profound mental state problems due to mild hypercalcaemia. Int J Geriatr Psychiatry 2002; 17 (7): 601-3
27. Vestergaard P, Mollerup CL, Frokjaer VG, et al. Cardiovascular events before and after surgery for primary hyperparathyroidism. World J Surg 2003; 27 (2): 216-22
28. Perkovic V, Hewitson TD, Kelynack KJ, et al. Parathyroid hormone has a prosclerotic effect on vascular smooth muscle cells. Kidney Blood Press Res 2003; 26 (1): 27-33
29. Pickard AL, Gridley G, Mellemkjae L, et al. Hyperparathyroidism and subsequent cancer risk in Denmark. Cancer 2002 Oct 15; 95 (8): 1611-7
30. Davies M, Fraser WD, Hosking DJ. The management of primary hyperparathyroidism. Clin Endocrinol 2002; 57: 145-55
31. Chen H, Parkerson S, Udelsman R. Parathyroidectomy in the elderly: do the benefits outweigh the risks? World J Surg 1998; 22:531-6
32. Chigot JP, Menegaux F, Achrafi H. Should primary hyperparathyroidism be treated surgically in elderly patients older than 75 years? Surgery 1995; 117: 397-401
33. Tibblin S, Palsson N, Rydberg J. Hyperparathyroidism in the elderly. Ann Surg 1983; 197: 135-8
34. Dodds C. Anaesthetic drugs in the elderly. Pharmacol Ther 1995; 66 (2): 369-86
35. Taillefer R, Boucher Y, Potvin C, et al. Detection and localisation of parathyroid adenomas in patients with hyperparathyroidism using a single radionuclide imaging procedure with m99Tc sestamibi (double phase study). J Nucl Med 1992; 33: 1801-7
36. Denham DW, Norman J. Cost effectiveness of preoperative sestamibi scans for primary hyperparathyroidism is dependent solely upon the surgeon's choice of operative procedure. J Am Coll Surg 1998; 186: 293-305
37. Geatti O. Parathyroid scintigraphy. Q J Nucl Med 1999; 43: 207-16
38. Lumachi F, Ermani M, Basso S, et al. Localization of parathyroid tumours in the minimally invasive era: which technique should be chosen? Population-based analysis of 253 patients undergoing parathyroidectomy and factors affecting parathyroid gland detection. Endocr Relat Cancer 2001; 8 (1): 63-9
39. Inabnet WB, Fulla Y, Richard B, et al. Unilateral neck exploration under local anaesthesia: the approach of choice for asymptomatic primary hyperparathyroidism. Surgery 1999; 126: 1004-9
40. Udelsman R. Six hundred fifty six consecutive explorations for primary hyperparathyroidism. Ann Surg 2002; 235: 665-72
41. Dillavou ED, Cohn HE. Minimally invasive parathyroidectomy: 101 consecutive cases from a single surgeon. J Am Coll Surg 2003; 197: 1-7
42. Biertho L, Chu C, Inabnet WB. Image-directed parathyroidectomy under local anaesthesia in the elderly. Br J Surg 2003, 742
43. Clark OH. Surgical treatment of primary hyperparathyroidism. Adv Endocrinol Metab 1995; 6: 1-6
44. Delbridge LW, Younes NA, Guinea AI, et al. Surgery for primary hyperparathyroidism 1962-1996: indication and outcome. Med J Aust 1998; 168: 153-6
45. Low RA, Katz AD. Parathyroidectomy via bilateral exploration: a retrospective review of 866 patients. Head Neck 1998; 20: 583-7
46. Tibblin S, Bondeson AG, Ljungberg O. Unilateral parathyroidectomy in hyperparathyroidism due to a single adenoma. Ann Surg 1982;195:245-52
47. Vogel LM, Lucas R, Czako P. Unilateral parathyroid exploration. Am Surg 1998; 64: 693-6
48. Gurnell EM, Poultsidis A, McFarlane I, et al. Pilot study of minimally invasive parathyroid surgery, with intraoperative parathyroid hormone measurement, as a day-case procedure. Br J Surg 2002; 89: 1332-3
49. Brunaud L, Zarnegar R, Wada N, et al. Incision length for standard thyroidectomy and parathyroidectomy. Br J Surg 2002; 89: 1331-2
50. Gene H, Monta E, Perrier ND, et al. Differing histologic findings after bilateral and focused parathyroidectomy. J Am Coll Surg 2003; 196: 535-40
51. Uden P, Chan A, Duh QY, et al. Primary hyperparathyroidism in younger and older patients: symptoms and outcome of surgery. World J Surg 1992; 16: 791-8
52. Chu C, Biertho L, Inabnet WB. Image-directed parathyroidectomy under local anaesthesia in the elderly [abstract]. Br J Surg 2002; 89: 1333
53. Monchik JM, Barellini L, Langer P, et al. Minimally invasive parathyroid surgery in 103 patients with local/regional anaesthesia, without exclusion criteria. Surgery 2002; 131: 502-8
54. Mannix Jr H, Pyrtek LJ, Crombie Jr HD, et al. Hyperparathyroidism in the elderly. Am J Surg 1980; 139: 581-5
55. Ozbas S, Pain S, Tang T, et al. Surgical management of primary hyperparathyroidism: results of a national survey. Ann R Coll Surg Engl 2003; 85: 236-41
56. Mandal AK, Udelsman R. Secondary hyperparathyroidism is an expected consequence of parathyroidectomy for primary hyperparathyroidism: a prospective study. Surgery 1998; 124: 1021-6
57. Abdelhadi M, Nordenstrom J. Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism. J Clin Endocrinol Metab 1998; 83: 3845-51
58. Abe Y, Ejima E, Fujiyama K, et al. Parathyroidectomy for primary hyperparathyroidism induces positive uncoupling and increases bone mineral density in cancellous bones. Clin Endocrinol 2000; 52: 203-9
59. Christiansen P, Steiniche T, Brixen K, et al. Primary hyperparathyroidism: effect of parathyroidectomy on regional bone mineral density in Danish patients: a three year follow-up study. Bone 1999; 25: 589-95
60. Brown EM. Physiology and pathophysiology of the extracellular calcium-sensing receptor. Am J Med 1999; 106: 238-53
61. Chattopadhyay N. Biochemistry, physiology and pathophysiology of the extracellular calcium-sensing receptor. Int J Biochem Cell Biol 2000; 32: 789-804
62. Nemeth EF, Steffey ME, Hammerland LG, et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci U S A 1998; 95: 4040-5
63. Fox J, Lowe SH, Petty BA, et al. NPS R-568: a type II calcimimetic compound that acts on parathyroid cell calcium receptor in rats to reduceplasma levels of parathyroid hormone and calcium. J Pharmacol Exp Ther 1999; 290: 473-9
64. Fox J, Lowe SH, Conklin RL, et al. Calcimimetic compound NPS R-568 stimulates calcitonin secretion but selectively targets parathyroid gland Ca (2+) receptor in rats. J Pharmacol Exp Ther 1999; 290: 480-6
65. Heath HI, Sanguinetti ES, Ogelsby S, et al. Inhibition of human parthyroid hormone secretion in-vivo by NPS R-568, a calcimimetic drug that targets the parathyroid cell-surface calcium receptor [abstract]. Bone 1995; 16: 85S
66. Goodman WG, Frazao JM, Goodkin DA, et al. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 2000; 58: 436-45
67. Silverberg SJ, Bone III HG, Marriott TB, et al. Short-term inhibition of parathyroid hormone secretion by a calcium-eceptor agonist in patients with primary hyperparathyroidism. N Engl J Med 1997; 337: 1506-10
68. Peacock M, Shoback DM, Greth WE, et al. The calcimimetic AMG 073 reduces serum calcium (Ca) in patients with primary hyperparathyroidism (PHPT) [abstract]. J Bone Miner Res 2001; 16: 163
69. Peacock M, Bilezikian JP, Turner SA, et al. Long term treatment with the calcimimetic AMG 073 in patients with primary hyperparathyroidism (PHPT) [abstract]. The Endocrine Society 84th Annual Meeting; 2002 Jun 19-22; San Fransisco, OR21-1
70. Adami S, Zamberlan N, Milan M, et al. Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone. Bone Miner 1994; 25: 75-82
71. Reasner CA, Stone MD, Hosking DJ, et al. Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate. J Clin Endocrinol Metab 1993; 77: 1067-71
72. Ammann P, Herter-Clavel C, Lubrano A, et al. A single bisphosphonate infusion is associated with improved functional capacity in elderly subjects with primary hyperparathyroidism. Aging Clin Exp Res 2002; 15: 500-4
73. Rossini M, Gatti D, Isaia G, et al. Effects of oral alendronate in elderly patients with osteoporosis and mild hyperparathyroidism. J Bone Miner Res 2001; 16 (1): 113-9
74. Parker CR, Blackwell PJ, Fairbairn KJ, et al. Alendronate in the treatment of primary hyperparathyroid related osteoporosis: a 2 year study. J Clin Endocrinol Metab 2002; 87: 4482-9
75. Mundy GR, Cove DH, Fisken R. Primary hyperparathyroidism changes in the pattern of clinical presentation. Lancet 1980; I: 1317-20
76. Gallagher JC, Nordin BE. Treatment with oestrogen of primary hyperparathyroidism in post menopausal women. Lancet 1972; I: 503-7
77. Marcus R, Madvig P, Crim M, et al. Conjugated estrogens in the treatment of postmenopausal women with hyperparathyroidism. Ann Intern Med 1984; 100: 633-40
78. Selby PL, Peacock M. Ethinyl estradiol and norethisterone in the treatment of primary hyperparathyroidism in postmenopausal women. N Engl J Med 1986; 314: 1481-5
79. Horowitz M, Wishart J, Need AG, et al. Treatment of postmenopausal hyperparathyroidism with norethindrone. Arch Intern Med 1987; 147: 681-5
80. Ettimger B, Black DM, Mitlak BH, et al. Reduction in vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 1999; 282: 637-45
81. Rubin MR, Lee KH, McMahon DJ, et al. Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2003; 88 (3): 1174-8
82. Zanchetta JR, Bogado CE. Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism. J Bone Miner Res 2001, 190
83. McDermott MT, Perloff JJ, Kidd GS. Effects of mild asymptomatic hyperparathyroidism on bone mass in women with and without estrogen replacement therapy. J Bone Miner Res 1994; 9: 509-14
84. Orr-Walker BJ, Evans MC, Clearwater JM, et al. Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four year follow-up and comparison with healthy postmenopausal women. Arch Intern Med 2000; 160: 2161-6
85. Diamond T, Ng ATM, Levy S, et al. Estrogen replacement may be an alternative to parathyroid surgery for the treatment of osteoporosisin elderly postmenopausal women presenting with primary hyperparathyroidism: a preliminary report. Osteoporosis Int 1996; 6: 329-33
86. Silverberg S, Gartenberg F, Jacobs TP, et al. Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism. J Clin Endocrinol Metab 1995; 80: 723-8
87. Horiuchi T, Onouchi T, Inoue J, et al. A strategy for the management of elderly women with primary hyperparathroidism; a comparison of etidronate therapy with parathyroidectomy. Gerontology 2002; 48: 103-8
88. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-41